News | May 10, 2021
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The facility is expected to be completed in 2024
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Subscribe To Our Newsletter & Stay Updated
